健之佳(605266.SH):意向收購重組後的唐人醫藥80%-100%股權
格隆匯2月28日丨健之佳(605266.SH)公佈,公司擬通過支付現金方式收購重組後河北唐人醫藥股份有限公司(簡稱“標的公司”或“唐人醫藥”)股東合計持有的唐人醫藥80%-100%股權(簡稱“交易標的”),達到控股或全資控制唐人醫藥的目的,以實現對唐人醫藥連鎖藥房品牌及直營門店、各項經營資產、經營資源及其經營權益的併購,推進公司在以京津冀為核心的環渤海地區業務拓展。
2022年2月28日,公司與王冠珏、趙明、王成舉、趙亮、趙超越、唐山市路北區佳仁企業管理諮詢服務中心(有限合夥)及唐人醫藥簽訂《股權收購意向協議》,各方就公司以現金方式受讓重組後唐人醫藥股東合計持有的唐人醫藥80%-100%股權達成初步意向。最終收購股權比例、交易對方及交易價格由交易各方協商確定。上述事項已經公司第五屆董事會第十四次會議審議通過。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.